Biosimilar Incentives: US Senate Republicans ‘Leery’ Of Out-Of-Pocket, Shared Savings Policies
Executive Summary
Senate Finance Committee staffer explains Republicans are inclined to support more moderate approaches in the near term as the 'bigger ideas' for promoting biosimilars evolve.
You may also be interested in...
Biosimilar Use, Cost Trends In Medicare Part B Will Be Examined By HHS Inspector General
If study finds biosimilar uptake in the Part B program is lagging, it may inform policy changes to encourage gains. On the other hand, the latest biosimilars trend reports from Cardinal Health and Amgen show follow-ons are controlling share in some markets for physician-administered drugs and savings are adding up.
Biosimilar Use, Cost Trends In Medicare Part B Will Be Examined By HHS Inspector General
If study finds biosimilar uptake in the Part B program is lagging, it may inform policy changes to encourage gains. On the other hand, the latest biosimilars trend reports from Cardinal Health and Amgen show follow-ons are controlling share in some markets for physician-administered drugs and savings are adding up.
FDA And FTC Offer Advice On Biosimilar Barriers
Speakers suggest ways to eliminate barriers to biosimilar uptake, but Janssen pushes back, saying there is need to inform physicians and patients of a biosimilar's interchangeability status. Biosimilar advocates want prescriber incentives, labeling changes, and FDA education on interchangeability.